VRET Adoption in Spain 2026: Barriers and Opportunities

Why a Sector Snapshot Matters Now

The conversation about virtual reality in clinical psychology swings between two not-very-useful extremes: generic technological hype ("VR will change therapy") and skepticism rooted in the pioneering experiences of the 2000s, with heavy headsets and limited graphics.

Neither picture describes the real state of the sector in Spain in 2026. This article tries to offer a sober snapshot of the moment: how many practices use it, where, why most still don't, and what signals from the broader European landscape let us anticipate the adoption curve of the next five years. The goal is to give you the judgment to decide when and how to get in, if your practice justifies it.

How Many Spanish Practices Use VR in 2026: An Estimate

There is no official registry of practices using VRET in Spain. The figures in circulation are estimates derived from three cross-referenced sources: headset distributors in the health B2B channel, clinical VR software providers with a presence in Spain, and conference presentations at the Consejo General de la Psicología (COP, Spain's national psychology council) and the Asociación Española de Psicología Clínica y Psicopatología (AEPCP, the Spanish clinical psychology association).

Cross-referencing those sources, a reasonable estimate as of May 2026 is: between 600 and 1,200 private clinical psychology practices in Spain use VR regularly. Out of an estimated 25,000-30,000 licensed psychologists in private practice (PsiCol), that represents between 2% and 4%.

The geographic distribution is concentrated: Madrid and Catalonia together account for approximately 55% of active practices, followed by the Valencian Community (12-15%), Andalusia (8-10%), and the Basque Country (5-7%). The rest of the country has a very minor presence.

By practice type, solo or two-psychologist private practices predominate (around 65% of active cases), followed by mid-sized multidisciplinary centers (25%) and, to a lesser extent, large innovation-oriented clinics (10%). Presence within the public health system is practically residual, limited to pilot projects at university hospitals.

Who Uses It: Profile of the Early Adopter

The psychologist who has incorporated VR into practice in Spain in 2026 fits a recognizable profile.

They are between 35 and 50 years old, have been licensed for 8 to 20 years, and work in their own private practice or at a center with clinical autonomy. Their predominant theoretical orientation is cognitive-behavioral or integrative with a CBT base.

Their practice concentrates on anxiety disorders (specific phobias, social anxiety, panic disorder with agoraphobia), trauma-related disorders (PTSD), and, to a lesser extent, OCD and somatoform disorders.

They likely combine VR with in vivo techniques and classic cognitive work, rather than replacing their practice with it. VR is a complement, not a replacement, in 95% of documented cases.

Their motivation is mixed: conviction from the clinical evidence (most have read at least one recent systematic review), competitive differentiation in their local market, and a reasoned curiosity about clinical innovation.

Barrier 1: Price and Economic Model

Price remains the most cited obstacle in informal sector surveys. But the real price has dropped drastically compared to 2018-2020.

In 2019, a bundled clinical VR solution (headset + software + support) cost between €4,000 and €8,000 upfront in Spain, plus annual fees of €1,200-2,500. In 2026, the equivalent entry cost is between €600 and €1,500 in hardware, with software subscriptions between €50 and €400/month depending on scale.

Psychologists who reject VR over price in 2026 are usually anchoring to a 2019 reference point that no longer holds, or haven't worked out the cost per session. A practice running eight VR sessions a week pays off the full equipment cost in six to twelve months, even with conservative rates.

Barrier 2: Insufficient Training Among the Average Licensed Psychologist

Official Spanish undergraduate and master's curricula in General Health Psychology (Psicología General Sanitaria) do not include specific training in virtual reality-mediated intervention as of 2026.

The newly licensed psychologist leaves university with solid knowledge of in vivo exposure and, in some programs, imaginal exposure, but without ever having seen a VR scenario.

Specialized postgraduate training exists (COP courses, conference workshops, vendor training), but it requires individual initiative. This explains part of the demographic skew toward mid-career psychologists with the purchasing power and time to train, versus newly licensed psychologists who would technically be the most receptive to the technology.

Barrier 3: Skepticism Based on Outdated Evidence

A significant minority of licensed Spanish psychologists still associate clinical VR with the uncomfortable experience of the 2005-2012 pioneers: heavy headsets, crude graphics, frequent motion sickness, lab-only software with no clinical polish.

The reality of 2026 is different: 500-gram headsets with inside-out tracking, packaged clinical software with a cockpit interface, commercial support, and scenarios specifically designed to minimize motion sickness.

The Carl et al. (2019) meta-analysis, NICE's reviews for psychosis (a conditional recommendation for gameChange following Freeman et al.'s 2022 results), and the updated Cochrane review of VR exposure for specific phobias (2023) have accumulated a body of evidence that can no longer be dismissed as anecdotal.

Skepticism in 2026 is usually informational skepticism: the psychologist hasn't updated their reading in the last five years, not because they read the evidence and disagreed with it. This matters for understanding that the barrier is less clinical resistance than a diffusion lag.

Barrier 4: Lack of Insurer Coverage

No private health insurer in Spain specifically reimburses virtual reality psychotherapy sessions as of 2026. Clinical psychology sessions are reimbursed under the usual schedule (individual psychotherapy session, €X) regardless of the technique used.

In practice, this isn't a direct financial barrier, since the reimbursement per session is the same. But it is a cultural signal: the insurance system treats VR as just another technique, not a differentiated modality, which slows the institutional pressure for practices to adopt it.

This will likely change in the next three to five years, especially if the UK model (the NHS has specifically reimbursed gameChange for psychosis since 2024) is replicated by continental private insurers.

European Signals Worth Watching

The UK is Europe's reference market. The gameChange program (Oxford University with the University of Manchester), validated in a multicenter randomized controlled trial (Freeman et al., Lancet Psychiatry 2022), has been integrated into the NHS catalog as an automated intervention for agoraphobia in psychosis. NHS Mental Health rolled out more than 100 installations under commercial license in 2024-2025. That deployment figure is the strongest signal of institutional adoption in Europe.

The Netherlands has CleVR as its leading provider, with partial insurer coverage and a presence in specialized mental health centers (GGZ). Adoption has consolidated over the last five years to the point of becoming mainstream in mid-sized Dutch practices.

Germany has seen Sympatient (Invirto, certified as a DiGA — Digital Health Application reimbursable by German public insurers) grow for specific phobias and social anxiety. Inclusion in the DiGA schedule is a strong signal of institutional validation.

France, Italy, and the Nordic countries are moving more slowly, with a presence in academic centers but limited commercial adoption.

Spain is roughly four to six years behind the UK in the pace of institutional adoption, but in line with the continental European average.

The Structural Opportunities Opening Up

For the psychologist considering entering now, there are four structural opportunities worth naming.

Competitive positioning in a fragmented market: the Spanish private psychology sector is highly atomized, and differentiation is hard. Offering VR is a differentiator that communicates clinical innovation and attracts patient profiles that value it (young adults, tech-oriented patients, referrals from specialist physicians with an innovation bias).

A head-start learning curve: whoever trains in clinical VR in 2026 accumulates three to five years of practice ahead of the cohort that enters once the modality becomes standard. It's a career asset that can't be replicated quickly.

Access to professional networks: VR practice and research groups in Spain are still small and receptive. Getting in now means getting in with a voice; getting in by 2030 will mean entering as just one more player in a mass market.

The ability to inform future health policy: practices that build up a body of clinical VR case data over the coming years will be a primary source if the SNS (Spain's National Health System) or insurers consider evaluating reimbursement. Documenting outcomes with validated instruments now is an investment with a multi-year payoff.

What to Expect in the Next 24-36 Months

The reasonable forecast, without promises, is that the number of active practices in Spain will roughly double between 2026 and 2029, moving from 2-4% to 5-9% of private practice.

Some impact-evaluation initiative within the National Health System is likely to emerge, especially in autonomous communities with a tradition of health pilots (Catalonia, Valencia, Madrid, the Basque Country). This doesn't imply widespread public reimbursement, but it does signal institutional legitimacy that could accelerate private adoption.

It's foreseeable that at least one Spanish private insurer will make a move during this period, whether through specific coding for VR sessions, discounts on corporate insurance plans that include them, or pilot coverage programs for specific phobias.

The question for the psychologist reading this isn't whether VR will become established in Spanish practice. The data suggest it will. The question is whether you want to be in the cohort of the first 1,000, the first 5,000, or the last 15,000 to adopt it.

A Note on VRET and This Article

VRET is one of the Spanish providers of clinical VR software. We have an obvious bias: it benefits us if the sector grows. In this article we've tried to describe the real state of the market, citing verifiable data and naming the barriers honestly, including those that affect our own adoption.

VRET is a tool that supports psychological intervention, not a CE-marked medical device. Clinical decisions and the treatment plan are the responsibility of the licensed psychologist.

This article is for informational purposes for psychology professionals. It is not clinical advice for any individual case and does not replace the judgment of the licensed psychologist in charge. VRET is professional clinical-support software, not a CE-marked medical device.